CXCR7 is a receptor for chemokines including CXCL12 (stromal-derived factor-1), a molecule that promotes tumor growth and metastasis in breast cancer and other malignancies. Building on the recent observation that CXCR7 sequesters CXCL12, we investigated mechanisms for CXCR7-dependent uptake of chemokines. Breast cancer cells expressing CXCR7 accumulated chemokines CXCL12 and CXC11 present at concentrations o1 ng/ml, unlike cells expressing CXCR4. CXCR7-dependent accumulation of chemokines was reduced by inhibitors of clathrin-mediated endocytosis. After CXCR7-mediated internalization, CXCL12 trafficked to lysosomes and was degraded, although levels of CXCR7 remained stable. CXCR7 reduced CXCL12 in the extracellular space, limiting the amounts of chemokine available to acutely stimulate signaling through CXCR4. CXCR7 constitutively internalized and recycled to the cell membrane even in the absence of ligand, and addition of chemokines did not significantly enhance receptor internalization. Chemokines at concentrations less than the Kd values for ligand-receptor binding did not alter levels of CXCR7 at the cell surface. Higher concentrations of chemokine ligands reduced the total cell surface expression of CXCR7 without affecting receptor internalization, indicating that receptor recycling was inhibited. CXCR7-dependent uptake of chemokines and receptor trafficking were regulated by b-arrestin 2. These studies establish mechanisms through which CXCR7 regulates the availability of chemokine ligands in the extracellular space.
Introduction
Chemokine CXCL12 (stromal-derived factor-1) signaling through receptor CXCR4 has been implicated in tumor progression and metastasis in breast cancer and in more than 20 other malignancies (Muller et al., 2001; Balkwill, 2004; Orimo et al., 2005; Luker and Luker, 2006; Kollmar et al., 2007; Zhang et al., 2007; Vandercappellen et al., 2008) . CXCL12 secreted by stromal fibroblasts in primary breast tumors increases the proliferation of tumor cells, as well as angiogenesis (Allinen et al., 2004; Orimo et al., 2005) . Gradients of CXCL12 are proposed to enhance cell migration, intravasation of cancer cells into the vasculature and organ-specific metastases (Muller et al., 2001; Kang et al., 2003; Smith et al., 2004) . More recently, chemokine CXCL11 (I-TAC) has been implicated in cancer, although functions of this molecule in malignancy are less defined. Some studies suggest that CXCL11 accelerates progression of malignancies such as ovarian cancer (Furuya et al., 2007; Atanackovic et al., 2008) , whereas other research indicates that this chemokine limits tumor growth by inhibiting angiogenesis or by directly reducing cell proliferation and survival (Yang et al., 2005) (Strieter et al., 2006) . Given multiple functions of CXCL12 and CXCL11 in cancer, molecules that control the availability of these chemokines will substantially affect tumor progression and represent potential therapeutic targets.
Bioavailability of chemokines is controlled by several different mechanisms. CXCL12 and CXCL11 bind to heparan sulfate glycosaminoglycans on cell membranes and extracellular proteins, increasing local concentrations of chemokines available for signaling (Laquri et al., 2007; Fermas et al., 2008) . Binding to glycosaminoglycans also protects chemokines from degradation by extracellular enzymes (Hoogewerf et al., 1997) . For both CXCL12 and CXCL11, extracellular proteases remove amino acids required for signaling through CXCR4 and CXCR3, respectively, and generate receptor antagonists (Proost et al., 2001; Sadir et al., 2004; Cox et al., 2008) . Proteolysis has been regarded as the primary mechanism for regulating signaling by secreted CXCL12 and CXCL11.
Chemokines may also be controlled by decoy receptors, which sequester chemokines without activating signaling pathways (Hansell et al., 2006) . Decoy receptors generally function as tumor suppressors. For example, decoy receptor D6 in breast cancer limits proliferation of malignant cells, tumor angiogenesis and metastasis in mice. D6 expression correlates positively with disease-free survival in patients (Wu et al., 2008) . Such studies further emphasize the effects of chemokines on tumor progression and metastasis.
Recent studies suggest that CXCR7 functions as a decoy receptor for CXCL12 (Boldajipour et al., 2008; Naumann et al., 2010) . CXCR7 removes CXCL12 from the extracellular space and is essential for migration of primordial germ cells in zebrafish, potentially by controlling gradients of CXCL12 to maintain signaling through CXCR4. However, mechanisms of action for CXCR7 in sequestering chemokines and the fate of internalized ligands remain undetermined, the latter of which is important because decoy receptors may degrade or release chemokines (Pruenster et al., 2009) .
In this study, we showed that CXCR7 internalized chemokine ligands and degraded these molecules in lysosomes, controlling the amounts of chemokines in the extracellular space for signaling through other receptors. Accumulation of chemokines was mediated by constitutive internalization and recycling of CXCR7 to the cell membrane. Elevated concentrations of chemokines did not significantly enhance CXCR7 internalization, but ligands more substantially reduced total CXCR7 on the cell surface. CXCR7-dependent uptake of chemokines and receptor internalization proceeded through clathrin-mediated endocytosis and through the cytosolic scaffolding protein b-arrestin 2. Association of CXCR7 with b-arrestin 2 also regulated ligand-dependent depletion of CXCR7 from the cell surface. These studies establish mechanisms through which CXCR7 regulates the availability of chemokines in the tumor microenvironment.
Results

CXCR7 promotes accumulation of chemokine ligands CXCL12 and CXCL11
To quantify CXCR7-dependent accumulation of chemokines, we used MDA-MB-231 human breast cancer cells stably transduced with CXCR7, CXCR4 or green fluorescent protein (GFP) (231-CXCR7, 231-CXCR4 and 231-control, respectively). MDA-MB-231 cells do not express endogenous CXCR7 (Luker et al., 2009a) . We incubated cells with E40, 4 or 0.8 ng/ml of CXCL12 fused to Gaussia luciferase (CXCL12-GL). CXCL12-GL retains normal signaling functions of unfused CXCL12 and allows quantification by bioluminescence imaging (Luker et al., 2009a) . For all concentrations of chemokine, 231-CXCR7 cells accumulated significantly more CXCL12-GL than 231-CXCR4 or 231-control cells within 1 h (Po0.01) (Figures 1a-c) . When incubated with 40 ng/ml CXCL12-GL, 231-CXCR7 cells accumulated increasing amounts of chemokine ( Figure 1a ). At lower concentrations near the E4 ng/ml Kd for CXCL12-CXCR7 binding (Balabanian et al., 2005; Burns et al., 2006) , CXCR7-mediated uptake of chemokine either reached steady state (4 ng/ml) or declined (0.8 ng/ml) after 1 h (Figures 1b and c) . Accumulation of CXCL12-GL did not differ between 231-CXCR4 and 231-control cells. 231-CXCR7 cells also accumulated CXCL11, the other ligand for this receptor, when incubated with CXCL11-GL at concentrations ranging from 0.8 to 30 ng/ml (Supplementary Figure S1A and B). These data show that CXCR7 promotes uptake and accumulation of even low concentrations of chemokine ligands. CXCR7 degrades CXCL12 and limits acute CXCR4 activation Internalized chemokines are typically degraded, although receptors including CXCR4 and Darc may resecrete chemokines into the extracellular space (Dar et al., 2005; Pruenster et al., 2009) . To investigate outcomes for internalized CXCL12, we pulse labeled 231-CXCR7 cells with E40 ng/ml CXCL12-GL and then switched cells to chemokine-free medium. Approximately 50% of the CXCL12-GL signal was lost after 4 h as quantified by bioluminescence in live cells and lysates ( Figure 2a and data not shown). Loss of CXCL12-GL was blocked by lysosomotropic agents chloroquine and NH 4 Cl (Po0.05), whereas treatment with proteasome inhibitor MG132 did not significantly increase levels of intracellular chemokine as determined by post hoc testing for multiple comparisons. Differences in levels of internalized CXCL12-GL were confirmed by western blotting (Supplementary Figure S2) . Degradation of CXCL11-GL in 231-CXCR7 cells was also inhibited by chloroquine (Supplementary Figure S3) , but CXCR7 itself remained stable as quantified with a CXCR7-GL fusion protein (Supplementary Figure S4) . Culture media from 231-CXCR7 cells during the 4-h chase period did not contain detectable CXCL12-GL (data not shown), showing that internalized chemokines were not released.
CXCL12-GL (40 ng/ml)
We used fluorescence microscopy to monitor intracellular localization of CXCR7 and internalized CXCL12. Under baseline conditions, intracellular CXCR7 partially colocalized with markers of late endosomes (Rab7) and lysosomes (Lamp) (Figures 2b  and c) . After incubation for 30 or 60 min with E8 ng/ml CXCL12-cherry fusion protein, some internalized chemokines localized with CXCR7-GFP in intracellular vesicles (Figure 2d and data not shown). Similar to CXCR7, CXCL12-cherry was present in Rab7-positive late endosomes and Lamp-positive lysosomes (Figures 
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Figure 2 CXCR7-dependent degradation of chemokines in lysosomes. (a) 231-CXCR7 cells were incubated with E40 ng/ml CXCL12-GL for 15 min, washed and then incubated without bioluminescent chemokine for 4 h in medium containing 50 mM chloroquine, 50 mM NH 4 CL, 25 mM MG132 or vehicle. Cells were acid washed to remove extracellular chemokine before bioluminescence imaging. Photons were normalized to total cellular protein in each sample, and data were expressed as mean values þ s.e.m. for percentage of initial uptake of CXCL12-GL after the 15 min pulse (n ¼ 4 each). *Po0.05. (b, c) 293T cells were cotransfected with CXCR7-citrine (depicted as green) and with either Rab7-CFP (b) or Lamp-CFP (depicted as red) (c), cultured in normal growth medium and imaged by fluorescence microscopy 2 days after transfection using an Â 40 objective. (d-f) 293T cells were transfected with CXCR7-GFP (d) or cotransfected with unfused CXCR7 and Rab7-CFP (e) or Lamp-CFP (f). Two days after transfection, cells were incubated for 30 min with E8 ng/ml CXCL12-cherry. Cells were fixed for fluorescence microscopy and viewed with an Â 40 objective. A full colour version of this figure is available at the Oncogene journal online. 2e and f), indicating that CXCR7 trafficks chemokines through late endosomes to lysosomes for degradation. Similar colocalization of CXCR7 with endogenous Rab7 and lysosomes was shown by immunostaining (Supplementary Figure S5) .
To quantify the effects of CXCR7 on extracellular CXCL12, we measured depletion of CXCL12-GL by 231-CXCR7 or 231-CXCR4 cells. From a starting concentration of E40 ng/ml CXCL12, there was an E50% loss of chemokine in medium incubated for a total of 1 h with 231-CXCR7 cells, whereas o20% of CXCL12-GL was depleted during incubation with 231-CXCR4 cells (Figure 3a ) (Po0.05). On using a comparable starting concentration of GL, losses of unfused enzyme did not differ between cell types and were indistinguishable from effects of 231-CXCR4 cells on CXCL12-GL.
Having established that CXCR7 decreases extracellular CXCL12, we measured effects on CXCR4 signaling on acute exposure to ligand. After incubation with 231-CXCR7 or 231-CXCR4 cells, we transferred medium containing the remaining CXCL12-GL to new 231-CXCR4 cells and analyzed the phosphorylation of AKT, a protein activated by CXCR4 signaling through Gai in 231 cells (Zhao et al., 2008) . There was reduced activation of AKT by CXCL12-GL in medium transferred from 231-CXCR7 cells relative to the medium from 231-CXCR4 cells (Figure 3b ). We also measured CXCL12-dependent recruitment of b-arrestin 2 to CXCR4, another early step in signaling, using firefly luciferase complementation (Luker et al., 2008) .
CXCL12-GL from 231-CXCR4 medium and CXCL12-GL that had not been preincubated with cells produced comparable complementation of b-arrestin 2 and CXCR4 ( Figure 3c ). Medium incubated with 231-CXCR7 cells produced significantly less activation of CXCR4, consistent with partial depletion of CXCL12-GL (Po0.05). Unfused GL had no effect on bioluminescence. These data establish that CXCR7-dependent depletion of CXCL12 from the extracellular space reduces acute CXCR4 signaling.
Chemokine regulation of CXCR7 internalization and cell surface expression Although signaling chemokine receptors typically remain at the cell surface until stimulated by ligand (Galliera et al., 2004; Weber et al., 2004) , decoy receptors may internalize constitutively. We used flow cytometry to quantify internalization of CXCR7 in the presence or absence of primaquine, an agent known to block recycling endosomes (van Weert et al., 2000) . In the absence of ligand, 485% of CXCR7 internalized from the surface of primaquine-treated cells within 30 min. Incubation with 100 ng/ml or more of CXCL12 minimally increased receptor internalization from the cell surface to E90% (Figure 4a ). Without primaquine, cell surface levels of CXCR7 decreased by only E55% after 30 min of incubation without ligand, showing that E30% of antibody-labeled receptors internalized and recycled to the cell membrane during this time. At X100 ng/ml concentrations of CXCL12, differences Approximately 75% of CXCR7 internalization occurred within 15 min, and treatment with 100 ng/ml CXCL12 only minimally increased the kinetics of receptor internalization ( Figure 4b ). CXCL11 at X100 ng/ml also modestly enhanced net internalization of CXCR7 (Po0.05 relative to untreated cells), suggesting that high concentrations of this chemokine may also limit recycling of internalized CXCR7 to the cell membrane (Supplementary Figure S6) . We measured the effects of ligands on total cell surface CXCR7. Over 30 min, levels of CXCR7 on the cell membrane remained relatively constant in untreated cells and in cells treated with up to 30 ng/ml CXCL12 (Figure 4c ). Higher concentrations of CXCL12 produced dose-dependent reductions in CXCR7 on the cell membrane, resulting in E65% less receptor at the surface after treatment with 1 mg/ml CXCL12 (Figure 4c ). Incubation with 100 ng/ml CXCL12 significantly decreased total cell surface CXCR7 by 15 min, with progressively greater reductions through 60 min (Po0.05 relative to untreated cells at comparable times) (Figure 4d ). Within the 60-min period of these assays, blocking protein synthesis with cycloheximide did not affect the results for total cell surface CXCR7 (data not shown). CXCL11 also produced dose-dependent reductions in total cell surface CXCR7 (Supplementary Figure S6) .
We investigated the internalization of endogenous CXCR7 in human MCF-7 breast cancer cells, which show CXCR7-dependent accumulation of CXCL12 (Luker et al., 2009a) . Approximately 70% of cell surface CXCR7 internalized in 30 min without ligand, and incubation with CXCL12 did not alter internalization significantly (Figure 5a ). Similar to 231-CXCR7 cells, almost all receptor internalization occurred within 15 min (Figure 5b ). However, primaquine did not increase net internalization of CXCR7 in MCF-7 cells (data not shown), indicating that kinetics of receptor recycling in these cells was slower than that in 231-CXCR7 cells. MCF-7 cells treated with X100 ng/ml CXCL12 had significantly reduced total CXCR7 on the cell membrane within 15 min of incubation, which persisted through 60 min (Po0.01) (Figures 5a and c) . These data establish that CXCR7 undergoes ligandindependent internalization with the extent and kinetics of recycling varying between breast cancer cell lines. Chemokines minimally alter receptor internalization while having more pronounced effects to reduce total levels of cell surface CXCR7.
b-Arrestin 2-dependent trafficking of CXCR7 and accumulation of CXCL12 We, along with others, have shown that CXCR7 interacts with b-arrestin 2, and ligand-dependent association of these proteins increases over time (Kalatskaya et al., 2009; Zabel et al., 2009; Luker et al., 2009c) . As barrestins mediate clathrin-mediated endocytosis and trafficking of several other chemokine receptors (Shenoy and Lefkowitz, 2003) , we hypothesized that uptake of chemokines and internalization of CXCR7 require b-arrestins. We initially incubated 231-CXCR7 cells with E4 ng/ml CXCL12-GL in the presence or absence of agents that disrupt clathrin-mediated endocytosis by blocking clathrin (hypertonic sucrose) or dynamin (dynasore) (Heuser and Anderson, 1989; Macia et al., 2006) . Each inhibitor significantly reduced the intracellular uptake of chemokine (Po0.05) (Figure 6a ), showing that CXCR7-dependent accumulation of ligands proceeds through clathrin-mediated endocytosis.
In addition to b-arrestin 2, the related adapter protein b-arrestin 1 may regulate endocytosis of chemokine and of seven other transmembrane receptors (Kohout et al., 2001) . We expressed CXCR7-GFP in b-arrestin 1
À/À and matched wild-type mouse embryonic fibroblasts (MEFs). Matched pairs of MEFs had comparable expression of CXCR7-GFP (Figure 6b ). Accumulation of CXCL12-GL did not differ between wild-type and b-arrestin 1 À/À MEFs, whereas accumulation was significantly lower in b-arrestin 2 À/À MEFs (Po0.01) (Figure 6c ). Uptake of CXCL12-GL was blocked by CCX733, a specific inhibitor of CXCR7. These studies show that b-arrestin 2 is required for CXCR7-dependent uptake of chemokines.
Using primaquine to block recycling endosomes, we showed that ligand-independent internalization of cell surface CXCR7 over 30 min was significantly greater in wild-type MEFs relative to that in b-arrestin 2 À/À MEFs (Figure 6d ) (Po0.05). Hypertonic sucrose also reduced ligand-dependent internalization of CXCR7 in 231-CXCR7 cells, providing further evidence for trafficking through clathrin-mediated endocytosis (Supplementary Figure S7) . Although loss of b-arrestin 2 did not alter total cell surface CXCR7 under basal conditions, CXCL12 reduced total cell surface CXCR7 to a greater extent in wild-type cells (Po0.01) (Figure 6e ). These results show that b-arrestin 2 regulates internalization and ligand-dependent depletion of CXCR7 from the cell membrane.
Removing CXCL12 increases receptor recycling
We hypothesized that CXCR7 and b-arrestin 2 would dissociate on removal of CXCL12, increasing recovery of receptors at the cell membrane. We quantified the association of CXCR7 and b-arrestin 2 using a firefly luciferase complementation assay (Luker et al., 2009c) . MDA-MB-231 breast cancer cells stably transduced with the CXCR7/b-arrestin complementation reporter were treated with 300 ng/ml CXCL12 for 30 min to promote association of CXCR7 and b-arrestin 2. After the removal of chemokine, bioluminescence decreased by E20% within 15 min and then declined gradually at subsequent time points, showing dissociation of CXCR7 and b-arrestin 2 (Figure 7a ). Consistent with our previous work, bioluminescence from association of CXCR7 and b-arrestin 2 increased over time when cells were maintained with CXCL12 (Po0.005) (Luker et al., 2009c) .
By flow cytometry, levels of CXCR7 at the cell surface increased by E25% within 15 min after removing CXCL12, with small additional increases through 2 h (Figure 7b ). Blocking protein synthesis with cycloheximide did not alter the recovery of cell surface CXCR7. Increases in cell membrane CXCR7 had kinetics similar to dissociation of CXCR7 and b-arrestin 2, suggesting that b-arrestin 2 contributes to intracellular retention of CXCR7. Cells incubated continuously with CXCL12 had minimal recovery of cell surface CXCR7, mediated largely by synthesis of new receptors. These data show that suppression of CXCR7 recycling by CXCL12 is reversed rapidly after the removal of ligand. 
Discussion
CXCR7 is expressed in malignant cells and in vascular endothelium in many human cancers (Raggo et al., 2005; Miao et al., 2007; Wang et al., 2008) , but mechanisms of action for this receptor remain poorly defined. CXCL11 and CXCL12, the known chemokine ligands for CXCR7, both regulate primary tumor growth and progression to metastatic disease in breast cancer and other common malignancies (Yang et al., 2005; Luker and Luker, 2006; Furuya et al., 2007; Atanackovic et al., 2008) . Therefore, functions of CXCR7 to control the availability of these chemokines may affect multiple steps in cancer progression. Establishing mechanisms of action for CXCR7 and its effects on homeostasis of these chemokines are essential for understanding chemokine signaling in cancer and for targeting these pathways for therapy.
We established that breast cancer cells expressing CXCR7 accumulated CXCL12 over a large range of concentrations in the extracellular space, unlike CXCR4, the other receptor for this chemokine. We also showed that CXCR7 promotes the uptake of CXCL11. Following CXCR7-dependent internalization, chemokines trafficked through Rab7-positive late endosomes to lysosomes for degradation and were not released back into the extracellular space. These results build on recent work showing that CXCR7 scavenges and degrades chemokine ligands (Boldajipour et al., 2008; Naumann et al., 2010) . Although internalized chemokines were degraded in cells expressing CXCR7, we established that the receptor remained stable. Stability of CXCR7 during internalization and degradation of chemokines likely contributes to its function as a decoy receptor, unlike CXCR4 and other receptors that may be degraded following ligand binding (Marchese and Benovic, 2001 ).
CXCR7 constitutively internalized and recycled to the cell surface in the absence of chemokine ligands, maintaining relatively constant levels of receptor at the cell membrane. Chemokines did not significantly increase receptor internalization. However, ligands at X100 ng/ml concentrations reduced total levels of CXCR7 at the cell membrane, likely by inhibiting receptor recycling. This concentration is considerably higher than Kd values for CXCL11 and CXCL12 binding to CXCR7 (E30 and E4 ng/ml for CXCL11 and CXCL12, respectively) (Balabanian et al., 2005; Burns et al., 2006) . Receptor internalization and accumulation of chemokines were partially dependent on b-arrestin 2, indicating that constitutive internalization of CXCR7 is necessary for uptake of chemokines from the extracellular space. Recycling of CXCR7 to the cell surface after incubation with CXCL12 had kinetics comparable to that of dissociation of CXCR7 and b-arrestin 2, further indicating that b-arrestin 2 regulates trafficking of CXCR7. Trafficking of CXCR7 most closely parallels decoy receptor D6, although chemokine ligands for D6 increase levels of receptor at the cell membrane (Galliera et al., 2004; Weber et al., 2004) . Further studies are needed to establish how different concentrations of chemokine ligands regulate the extent and kinetics of CXCR7 recycling. By removing chemokines from the extracellular environment, CXCR7 regulates signaling through CXCR4. CXCR7-mediated depletion of CXCL12 reduces acute activation of CXCR4 and its downstream signaling pathways. Similar results for the effects of CXCR7 on immediate responses of CXCR4 to CXCL12 have been described, although the previous study reported that cells expressing CXCR7 completely abrogated CXCR4 signaling rather than decreasing it as we observed (Boldajipour et al., 2008) . Although we used the same experimental protocol as the previous study, differing results may be due to discordant concentrations of CXCL12 and/or expression levels of CXCR4 and/or CXCR7. Nevertheless, both studies show that CXCR7 limits CXCL12-CXCR4 signaling in response to short-term stimulation.
CXCR7-dependent depletion of CXCL12 and inhibition of short-term CXCR4 signaling might be expected to oppose effects of CXCL12-CXCR4 on growth and metastasis of cancer cells. However, CXCR7 increases tumor progression in animal models of several different cancers (Raggo et al., 2005; Miao et al., 2007; Wang et al., 2008) . Although some effects of CXCR7 in cancer are independent of CXCR4, CXCR7 is known to heterodimerize with CXCR4 and modify CXCR4 signaling, suggesting that CXCR7 may combine with CXCR4 to promote tumor growth and/or metatasis (Sierro et al., 2007; Levoye et al., 2009; Luker et al., 2009b) . Integrated functions of CXCR7 on somatic cells and of CXCR4 on germ cells are necessary for proper chemotaxis of the latter cell type during zebrafish development, wherein CXCR7 is proposed to maintain gradients of CXCL12 (Boldajipour et al., 2008) . As fundamental processes in development are frequently recapitulated in cancer, CXCR7 may control levels and distribution of CXCL12 in the tumor microenvironment to potentiate CXCR4 signaling in malignant and/or stromal cells. We are currently investigating the extent MEFs were incubated with E4 ng/ml CXCL12-GL for 30 min in medium containing 100 nM of the CXCR7-specific inhibitor CCX733 or vehicle. Cells were acid washed to remove extracellular chemokine before quantifying CXCL12-GL bioluminescence in living cells. Data were graphed as mean values for photons per mg protein±s.e.m. (n ¼ 4 each). (d) Wild-type and b-arrestin 2 À/À MEFs were incubated for 30 min with 1 mM primaquine in the presence or absence of 100 ng/ml CXCL12 for 30 min before quantifying the internalization of cell surface CXCR7 by flow cytometry. (e) MEFs were incubated for 30 min with or without 100 ng/ml CXCL12, and total mean fluorescence intensity for cell surface CXCR7 at the end of the incubation period was quantified by flow cytometry. Data in (d) and (e) were expressed as percentage of initial cell surface CXCR7 as in Figure 2 . *Po0.05; **Po0.01.
to which CXCR7 regulates the availability of CXCL12 and functions of CXCR4 in breast cancer in vivo. In summary, we established that CXCR7 undergoes constitutive internalization and ligand-regulated recycling regulated by b-arrestin 2 to accumulate and degrade chemokines. These results provide a mechanism through which CXCR7 may modify gradients of chemokines and chemokine receptor signaling in cancer. Functions of CXCR7 as a decoy receptor do not preclude alternative mechanisms of action, such as direct activation of signaling pathways or cellular responses Zabel et al., 2009) . Understanding the effects of CXCR7 on chemokine homeostasis in the tumor microenvironment will advance ongoing efforts to target chemokine receptors for therapy in breast cancer and other malignancies. (Luker et al., 2009a) . MDA-MB-231 cells stably expressing firefly luciferase complementation reporters for CXCR7 and b-arrestin 2 (CXCR7-NLuc and b-arrestin 2-CLuc) and 293T cells with CXCR4-NLuc and b-arrestin 2-CLuc have been described (Luker et al., 2008 (Luker et al., , 2009c .
Materials and methods
Cells
Plasmids
To fuse CXCR7 to GL (CXCR7-GL), we digested CXCR7-GFP with EcoRI and NotI and replaced GFP with GL from CXCL12-GL (Luker et al., 2009a) . GL used in fusion constructs lacks the native secretion signal. We fused CXCL12 to mCherry (Roger Tsien, University of California, San Diego, CA, USA) by digesting the CXCL12-GL plasmid with EcoRI and NotI and replacing GL with mCherry. To fuse CXCR7 to fluorescent protein citrine (Griesbeck et al., 2001) , we digested CXCR7GFP with AgeI and NotI to remove GFP and insert citrine (Luker et al., 2009c) . Rab7-CFP and Lamp-CFP fusion proteins were provided by Joel Swanson (University of Michigan, Ann Arbor, MI, USA).
Lentiviruses
Lentiviruses were prepared by transient transfection of 293T cells and used to stably express CXCR7-GFP in MEFs (Lois et al., 2002; Luker et al., 2009c) .
Chemokine supernatants CXCL11 or CXCL12 fused to GL (CXCL11-GL or CXCL12-GL) was prepared from 293T cells (Luker et al., 2009a) . Concentrations of chemokines were determined using standard curves of bioluminescence relative to amounts of chemokine determined by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA) (Luker et al., 2009a) .
Accumulation of bioluminescent chemokines
Cells were plated into black wall 96-well plates (1.5 Â 10 4 cells per well) and used the following day. Cells were incubated with CXCL11-GL or CXCL12-GL diluted in DMEM with 0.2% bovine serum albumin (BSA) (Probumin, Millipore, Billerica, MA, USA). In selected experiments, cells were incubated with 0.4 M sucrose (Sigma, St Louis, MO, USA), 80 mM dynasore (Sigma) or vehicle for 30 min before adding bioluminescent chemokine. To measure chemokine degradation, cells were incubated with CXCL11-or CXCL12-GL for 15 min, washed twice with phosphate-buffered saline and then incubated for 4 h in DMEM consisting of 0.2% BSA containing 50 mM chloroquine, 50 mM NH 4 Cl, 25 mM MG132 (Sigma) or vehicle. After incubations, cells were washed twice with acidic solution (0.2 M acetic acid, 0.5 m NaCl) at 4 1C, followed by phosphate buffered saline to remove extracellular chemokine (Kelly et al., 2006; Luker et al., 2009c) . Bioluminescence imaging in live cells was performed on an IVIS 100 (Caliper, Hopkinton, MA, USA) (Luker et al., 2008 (Luker et al., , 2009a . Data were quantified as photons and normalized to cellular protein determined by sulforhodamine B (Sharma et al., 1996) .
Fluorescence microscopy 293T cells were transfected with CXCR7-citrine or unfused CXCR7 in combination with Rab7-CFP or Lamp-CFP. Alternatively, cells were transfected with CXCR7-GFP. Two days after transfection, cells were analyzed under baseline conditions or following incubation with E8 ng/ml CXCL12-cherry in DMEM with 0.2% BSA for 30 or 60 min. Cells were washed once with phosphate-buffered saline, fixed in 2% formaldehyde solution in phosphate-buffered saline for 5 min and then mounted with fluorescent mounting medium (Prolong Gold, Invitrogen, Carlsbad, CA, USA). Slides were viewed by epifluorescence microscopy using an Â 40 objective.
Chemokine depletion 231-CXCR4 or 231-CXCR7 cells were plated in 96-well plates as described above. CXCL12-GL or unfused GL supernatants were incubated with 231 cells for 30 min, transferred to cells expressing the same receptor and incubated for an additional 30 min. Supernatants were then transferred to 231-CXCR4 cells that had been cultured overnight in DMEM medium with 0.2% BSA. Cells were lysed after 5 min and probed by western blotting for phospho-473 and total AKT (Cell Signaling, Danvers, MA, USA) (Luker et al., 2009a) . Alternatively, CXCL12-GL supernatants were transferred to 293T cells expressing firefly luciferase complementation reporters for CXCR4/b-arrestin 2 and incubated for 10 min before quantifying bioluminescence. We also measured bioluminescence from CXCL12-GL or unfused GL in 5 ml of supernatants.
Flow cytometry
Internalization of CXCR7 from the cell surface was measured by flow cytometry (Galliera et al., 2004) . Cells were washed with DMEM containing 1% BSA and 25 mM Hepes, pH 7.4 (DMEM containing 1% BSA). Cells were incubated with mAb 11G8 to CXCR7 (gift of ChemoCentryx, Mountain View, CA, USA) for 1 h on ice, washed twice with DMEM containing 1% BSA, resuspended in DMEM containing 1% BSA without or with CXCL12 or 1 mM primaquine (Sigma) as indicated, and shifted to 37 1C. In selected experiments, cells were incubated with 0.4 M sucrose or vehicle for 30 min on ice before shifting to 37 1C. Control cells were maintained on ice. All samples were washed twice with cold DMEM containing 1% BSA and incubated for 30 min on ice with 1:200 dilution of allophycocyanin-conjugated donkey anti-mouse antibody (Jackson ImmunoResearch, West Grove, PA, USA). To determine total cell surface CXCR7 after incubation at 37 1C, cells were again incubated with anti-CXCR7 antibody, washed twice with DMEM containing 1% BSA and then stained with secondary antibody.
To analyze the effects of protein synthesis on recovery of cell surface CXCR7, cells were incubated at 37 1C for 30 min in DMEM containing 1% BSA without or with 300 ng/ml CXCL12. Cells incubated with CXCL12 were either maintained with CXCL12 or washed twice with DMEM containing 1% BSA and transferred to medium without CXCL12. Cycloheximide (100 mg/ml) (Sigma) was added to subsets of cells to block protein synthesis during 2-h incubation at 37 1C (Luker et al., 2003) . Staining for cell surface CXCR7 was performed as described.
Cells were analyzed by flow cytometry using FACSAria (BD Biosciences, San Jose, CA, USA), collecting X1 Â 10 4 events per sample. CXCR7 internalization was calculated using mean fluorescence intensity of allophycocyanin for cells incubated at 37 1C and for those maintained on ice (Galliera et al., 2004) . Total receptor on the cell surface following incubation at 37 1C was assessed by mean fluorescence intensity of allophycocyanin for cells restained with primary antibody.
Firefly luciferase complementation for interactions between CXCR7 and b-arrestin 2 231 breast cancer cells stably expressing CXCR7-NLuc and b-arrestin 2-CLuc were incubated at 37 1C with 300 ng/ml CXCL12. Cells were either maintained in medium containing CXCL12 or washed twice with DMEM containing 1% BSA and incubated without CXCL12 for various times through 2 h. Firefly luciferase activity was quantified as described (Luker et al., 2008) .
Statistics
Data were plotted as mean values with s.e.m. Cell culture experiments were performed 2-5 times each, and representative data were presented. Statistically significant differences (Po0.05) were determined by the Mann-Whitney U test (GraphPad Prism, La Jolla, CA, USA). Dunn's multiple comparison test was used for post hoc analysis of groups of data.
